This week, 5 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Bellicum Pharmaceuticals Inc (BLCM) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of BLCM stock.

The rating of Summit Therapeutics PLC Sponsored ADR (SMMT) moves up this week, rising from a C to a B. For more information, get Portfolio Grader’s complete analysis of SMMT stock.

This is a strong week for CytomX Therapeutics, Inc. (CTMX). The company’s rating climbs to B from the previous week’s C. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of CTMX stock.

Sinovac Biotech Ltd. (SVA) gets a higher grade this week, advancing from a C last week to a B. Sinovac Biotech Ltd. researches, develops, manufactures, and markets various vaccines, including flu vaccines and vaccines for Hepatitis A. For more information, get Portfolio Grader’s complete analysis of SVA stock.

Kindred Biosciences, Inc. (KIN) boosts its rating from a C to a B this week. For more information, get Portfolio Grader’s complete analysis of KIN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.